Are selective estrogen receptor modulators (SERMs) a therapeutic option for HPV-associated cervical lesions and cancers?

American Journal of Pathology

Volumn 184, Issue 2, 2014, Pages 358-361

  Munger, Karl ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCARCINOGEN; ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

CARCINOGENESIS; DISEASE COURSE; GENE EXPRESSION; HUMAN; NONHUMAN; NOTE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; WART VIRUS;

ANIMALS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERINE CERVICAL NEOPLASMS;

EID: 84892159393     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.11.005     Document Type: Note

References (24)

1. M.E. Spurgeon, S.H. Chung, and P.F. Lambert Recurrence of cervical cancer in mice following selective estrogen receptor modulator therapy Am J Path 184 2014 530 540
2. S.H. Chung, and P.F. Lambert Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists Proc Natl Acad Sci U S A 106 2009 19467 19472
3. M. Schiffman, P.E. Castle, J. Jeronimo, A.C. Rodriguez, and S. Wacholder Human papillomavirus and cervical cancer Lancet 370 2007 890 907
4. M.L. Gillison, W.M. Koch, R.B. Capone, M. Spafford, W.H. Westra, L. Wu, M.L. Zahurak, R.W. Daniel, M. Viglione, D.E. Symer, K.V. Shah, and D. Sidransky Evidence for a causal association between human papillomavirus and a subset of head and neck cancers J Natl Cancer Inst 92 2000 709 720
5. M.E. McLaughlin-Drubin, J. Meyers, and K. Munger Cancer associated human papillomaviruses Curr Opin Virol 2 2012 459 466
6. S. Vaccarella, R. Herrero, P.J. Snijders, M. Dai, J.O. Thomas, N.T. Hieu, C. Ferreccio, E. Matos, H. Posso, S. de Sanjose, H.R. Shin, S. Sukvirach, E. Lazcano-Ponce, N. Munoz, C.J. Meijer, S. Franceschi IARC HPV Prevalence Surveys (IHPS) Study Group Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys I J Epidemiol 37 2008 536 546
7. S.H. Chung, S. Franceschi, and P.F. Lambert Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab 21 2010 504 511
8. J.M. Arbeit, P.M. Howley, and D. Hanahan Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice Proc Natl Acad Sci U S A 93 1996 2930 2935
9. D.A. Elson, R.R. Riley, A. Lacey, G. Thordarson, F.J. Talamantes, and J.M. Arbeit Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis Cancer Res 60 2000 1267 1275
10. S.H. Chung, M.K. Shin, K.S. Korach, and P.F. Lambert Requirement for stromal estrogen receptor alpha in cervical neoplasia Horm Cancer 4 2013 50 59
11. M.K. Stelzer, H.C. Pitot, A. Liem, J. Schweizer, C. Mahoney, and P.F. Lambert A mouse model for human anal cancer Cancer Prev Res (Phila) 3 2010 1534 1541
12. K. Strati, H.C. Pitot, and P.F. Lambert Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model Proc Natl Acad Sci U S A 103 2006 14152 14157
13. S.H. Chung, K. Wiedmeyer, A. Shai, K.S. Korach, and P.F. Lambert Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer Cancer Res 68 2008 9928 9934
14. M. Herfs, Y. Yamamoto, A. Laury, X. Wang, M.R. Nucci, M.E. McLaughlin-Drubin, K. Munger, S. Feldman, F.D. McKeon, W. Xian, and C.P. Crum A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer Proc Natl Acad Sci U S A 109 2012 10516 10521
15. S.F. Jabbar, S. Park, J. Schweizer, M. Berard-Bergery, H.C. Pitot, D. Lee, and P.F. Lambert Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein Cancer Res 72 2012 4008 4016
16. T. Brake, and P.F. Lambert Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model Proc Natl Acad Sci U S A 102 2005 2490 2495
17. E.M. Smith, S.R. Johnson, E.J. Figuerres, M. Mendoza, D. Fedderson, T.H. Haugen, and L.P. Turek The frequency of human papillomavirus detection in postmenopausal women on hormone replacement therapy Gynecol Oncol 65 1997 441 446
18. J.V. Lacey Jr., L.A. Brinton, W.A. Barnes, P.E. Gravitt, M.D. Greenberg, O.C. Hadjimichael, L. McGowan, R. Mortel, P.E. Schwartz, R.J. Kurman, and A. Hildesheim Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix Gynecol Oncol 77 2000 149 154
19. A. Gadducci, C. Barsotti, S. Cosio, L. Domenici, and A. Riccardo Genazzani Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature Gynecol Endocrinol 27 2011 597 604
20. P.E. Castle Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials Int J Cancer 128 2011 997 998
21. E. Barrett-Connor, L. Mosca, P. Collins, M.J. Geiger, D. Grady, M. Kornitzer, M.A. McNabb, and N.K. Wenger Raloxifene Use for The Heart Trial I: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 355 2006 125 137
22. L. Reimers, and K.D. Crew Tamoxifen vs raloxifene vs exemestane for chemoprevention Curr Breast Cancer Rep 4 2012 207 215
23. R.K. Gara, V. Sundram, S.C. Chauhan, and M. Jaggi Anti-cancer potential of a novel SERM ormeloxifene Curr Med Chem 20 2013 4177 4184
24. T. Brake, J.P. Connor, D.G. Petereit, and P.F. Lambert Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer Cancer Res 63 2003 8173 8180